Literature DB >> 23053509

Is paromomycin the drug of choice for eradication of Blastocystis in adults?

Jaap J van Hellemond1, Nicky Molhoek, Rob Koelewijn, Pieter J Wismans, Perry J J van Genderen.   

Abstract

Blastocystis is a protozoan parasite of controversial clinical significance that is often detected in stools of patients with gastrointestinal complaints. Patients infected with Blastocystis and persistent, unexplained gastrointestinal complaints are often treated with the intention to eradicate Blastocystis. However, there is no consensus on the most effective drug. We performed a retrospective follow-up study with a large cohort of patients in which the natural disease course and efficacy of treatment with either paromomycin, clioquinol, or metronidazole were evaluated. With an eradication rate of 77 %, treatment with paromomycin appeared significantly more effective than treatment with clioquinol (38 %), metronidazole (38 %), or no treatment (22 %). This study showed that (1) Blastocystis was frequently observed in the stools of our patient group (34 %), (2) spontaneous clearance of Blastocystis infections occurred only in a small proportion of patients (22 %), and therefore (3) drug treatment is required for more efficient eradication of Blastocystis. Paromomycin exhibited superior performance in comparison to both metronidazole and clioquinol.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053509     DOI: 10.1007/s10156-012-0496-2

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  8 in total

Review 1.  Understanding drug resistance in human intestinal protozoa.

Authors:  Hend Aly El-Taweel
Journal:  Parasitol Res       Date:  2015-03-19       Impact factor: 2.289

2.  Subtype determination of Blastocystis isolates by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS).

Authors:  D Martiny; A Bart; O Vandenberg; N Verhaar; E Wentink-Bonnema; C Moens; T van Gool
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-27       Impact factor: 3.267

3.  In Vitro Antimicrobial Susceptibility Patterns of Blastocystis.

Authors:  Tamalee Roberts; Stephen Bush; John Ellis; John Harkness; Damien Stark
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

4.  Intra-subtype variation in enteroadhesion accounts for differences in epithelial barrier disruption and is associated with metronidazole resistance in Blastocystis subtype-7.

Authors:  Zhaona Wu; Haris Mirza; Kevin Shyong Wei Tan
Journal:  PLoS Negl Trop Dis       Date:  2014-05-22

5.  Clinical pilot study: efficacy of triple antibiotic therapy in Blastocystis positive irritable bowel syndrome patients.

Authors:  Robyn Nagel; Helle Bielefeldt-Ohmann; Rebecca Traub
Journal:  Gut Pathog       Date:  2014-08-20       Impact factor: 4.181

6.  Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use.

Authors:  Masaaki Ishikawa; Nadia García-Mateo; Alen Čusak; Iris López-Hernández; Marta Fernández-Martínez; Marcus Müller; Lukas Rüttiger; Wibke Singer; Hubert Löwenheim; Gregor Kosec; Štefan Fujs; Luis Martínez-Martínez; Thomas Schimmang; Hrvoje Petković; Marlies Knipper; M Beatriz Durán-Alonso
Journal:  Sci Rep       Date:  2019-02-20       Impact factor: 4.379

7.  Blastocystis: Consensus of treatment and controversies.

Authors:  Uma Sekar; M Shanthi
Journal:  Trop Parasitol       Date:  2013-01

Review 8.  Parasitic diarrheal disease: drug development and targets.

Authors:  Amir Azam; Mudasir N Peerzada; Kamal Ahmad
Journal:  Front Microbiol       Date:  2015-10-27       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.